It could become a key disruptor if enough cannabis cultivators embrace the technology and realize that the advantages go beyond the obvious. As stated on their website, Pharmagreen’s primary focus is to produce pesticide/fungicide-free, with no genetic drift tissue cultured plantlets to meet the rapidly increasing Cannabis market demand for medicinal quality starter plant material using the proprietary in-vitro “Chibafreen Process”. It is already well-known using tissue culture propagation for new growth plantlets from any existing plant strain will limit genetic variance and mutation. It allows for large-scale production of precise and consistently robust quality suitable plantlets for even the most sizeable commercial ventures. Some of the other advantages that are overlooked are the fact that using TCP frees up all or substantial all of the mother room, which can free up as much as 20% more grow space. Also, Pharmagreen will dial into each strain and develop a protocol for the cultivators to maximize quality and yield.
OK …. And another one of my personal favourites … that four letter word starting with the letter “H” … Hemp! Many expect the hemp market (once one considers biofuel, textiles, building materials, plastics, etc) to potentially dwarf the cannabis market … and yes Hemp is a sativa but we always differentiate the two. How will Alliance participate in the Hemp industry?
B.R.I.M. has developed a proprietary industrial hemp strain named “CBD DANA” which will be made available for large-scale production for both domestic and international markets produced and sold via Pharmagreen’s biotech center, of which Alliance Growers with eventually share in 30% of this revenue stream by way of the purchase of a 30% equity and profit sharing interest. This innovative strain contains a high cannabidiol content of 10-20%, less than 0.3% THC and a unique profile of active terpene and alkamide entourage constituents. Access to the CBD Dana hemp strain is another advantage Alliance has over other companies in this space.
114